iNova Pharmaceuticals announces the launch of iPitch 2020
Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.
iPitch is a collaborative crowdsourcing program that allows product and packaging developers, innovators, licensors and certified manufacturers to connect with iNova and share their great ideas for healthcare products that have the potential for commercialisation.
It provides a wonderful opportunity for anyone with new and different ideas or next-generation solutions that may not have the resources or expertise to bring their innovations to market, or just looking for a commercialisation partner.
According to iNova Executive Director and Head of Innovation, Filomena Maiese, “We know there’s consumer health product innovations out there that haven’t yet been commercialised. We want to partner with them.”
iPitch specifically looks for effective, evidence-based products with innovative and new formats and formulations. After creating a lot of buzz last year, and by leveraging the power of global connectivity, the 2019 iPitch received hundreds of different and diverse product and formulation ideas from around the world. iNova is currently preparing to launch two of these products into the marketplace, which otherwise would not have had a chance to make it to consumers.
Entries for iPitch can be made according to criteria set out by iNova within a range of set ‘challenges’. This year, iNova has created and carefully selected a diverse set of challenges across which submissions can be made. This provides more opportunity for innovators to submit entries and captures ideas across a wide range of consumer healthcare needs. The challenges cover products from pregnancy supplements to packaging to face masks to cough, cold and flu formulations.
iNova is excited about building a number of new mutually beneficial business partnerships through iPitch. According to Chief Executive Officer, Dan Spira, “iNova has a strong track record of acquiring, building and launching trusted consumer healthcare brands, which makes us a great partner of choice for product owners and licensors globally”.
iNova has a diverse range of market-leading products. They have a trusted reputation among consumers and healthcare professionals and are recognised as an innovative partner of choice in the healthcare industry. With a multi-national business platform, it offers access to well-established operating platforms and broad distribution networks across Asia, Africa and ANZ.
iPitch will be open for applications for 12 weeks, ending 21 August 2020.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance